HC Wainwright restated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX – Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright also issued estimates for Kiora Pharmaceuticals’ Q2 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at $0.15 EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.
Kiora Pharmaceuticals Stock Performance
Shares of NASDAQ:KPRX opened at $0.53 on Monday. The firm has a 50 day moving average of $0.56 and a 200-day moving average of $0.58. Kiora Pharmaceuticals has a 12 month low of $0.45 and a 12 month high of $2.24.
Institutional Investors Weigh In On Kiora Pharmaceuticals
A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Rosalind Advisors Inc. acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,300,000 shares of the company’s stock, valued at approximately $1,624,000. Kiora Pharmaceuticals comprises about 1.5% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 22nd biggest position. Rosalind Advisors Inc. owned approximately 8.76% of Kiora Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 76.97% of the company’s stock.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Featured Articles
- Five stocks we like better than Kiora Pharmaceuticals
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- What is a Short Call Butterfly Spread? Explanation with Examples
- Low PE Growth Stocks: Unlocking Investment Opportunities
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- How Technical Indicators Can Help You Find Oversold Stocks
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.